| answer text |
<p>The National Institute for Health and Care Excellence (NICE) follows a rigorous
process in the appraisal of technologies to ensure that judgements regarding the cost-effective
use of NHS resources are consistently applied. This includes consideration of the
uncertainty generated where available data have serious limitations.</p><p> </p><p>When
making judgements on cost effectiveness, the NICE appraisal committee will consider
a number of factors including the strength of the clinical-effectiveness evidence,
the innovative nature of the technology, the robustness and plausibility of the economic
models, the degree of certainty around the incremental cost-effectiveness ratio (ICER),
the range and plausibility of the ICERs and the likelihood of decision error and its
consequences. Full details of how the Committee takes uncertainty into account is
contained within sections 5.8, 6.3 and 6.4 of NICE's Guide to the Methods of Technology
Appraisal 2013, which is available at:</p><p>http://publications.nice.org.uk/guide-to-the-methods-of-technology-appraisal-2013-pmg9</p><p>
</p><p>NICE advises that it has not carried out an assessment of the average range
around the most plausible cost-per Quality Adjusted Life Year (QALY) in its technology
appraisals. We understand that although NICE usually specifies the most plausible
cost-per-QALY for each technology appraisal, it does not normally specify a range
for this assessment.</p><p> </p>
|
|
